<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36810336</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e253388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2022-253388</ELocationID><Abstract><AbstractText>Fibrillar glomerulonephritis (FGN) is a rare proliferative form of glomerular disease characterised by randomly oriented fibrillar deposits with a mean diameter of 20&#x2009;nm. It has a rare association with systemic lupus erythematosus (SLE). We report the case of a female in her mid-50's with a 20&#x2009;year history of SLE, who developed proteinuria due to FGN and had no histological evidence of lupus nephritis. She was maintained on azathioprine and prednisolone. A renal biopsy revealed randomly arranged fibrillar deposits that positively stained for DNAJB9, consistent with a diagnosis of FGN. Azathioprine was switched to mycophenolate mofetil, and the patient showed significant improvement in proteinuria. This case-based review describes the diagnosis, management and clinical outcome of FGN in association with SLE in the absence of lupus nephritis.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whelband</LastName><ForeName>Matthew Carl</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-4819-3756</Identifier><AffiliationInfo><Affiliation>Acute Medicine, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, Norfolk, UK matthew.whelband@jpaget.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willingham</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thirunavukkarasu</LastName><ForeName>Sathiamalar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nephrology, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, Norfolk, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478021">DNAJB9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological agents</Keyword><Keyword MajorTopicYN="N">Pathology</Keyword><Keyword MajorTopicYN="N">Renal medicine</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>14</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36810336</ArticleId><ArticleId IdType="pmc">PMC9944728</ArticleId><ArticleId IdType="doi">10.1136/bcr-2022-253388</ArticleId><ArticleId IdType="pii">16/2/e253388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosenstock JL, Markowitz GS. Fibrillary glomerulonephritis: an update. Kidney Int Rep 2019;4:917&#x2013;22. 10.1016/j.ekir.2019.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2019.04.013</ArticleId><ArticleId IdType="pmc">PMC6611949</ArticleId><ArticleId IdType="pubmed">31317113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr SH, Vrana JA, Dasari S, et al. . DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep 2018;3:56&#x2013;64. 10.1016/j.ekir.2017.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2017.07.017</ArticleId><ArticleId IdType="pmc">PMC5762944</ArticleId><ArticleId IdType="pubmed">29340314</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskandar SS, Falk RJ, Jennette JC. Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int 1992;42:1401&#x2013;7. 10.1038/ki.1992.433</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1992.433</ArticleId><ArticleId IdType="pubmed">1474772</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr SH, Fogo AB. New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int 2019;96:581&#x2013;92. 10.1016/j.kint.2019.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.03.021</ArticleId><ArticleId IdType="pubmed">31227146</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock JL, Markowitz GS, Valeri AM, et al. . Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003;63:1450&#x2013;61. 10.1046/j.1523-1755.2003.00853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2003.00853.x</ArticleId><ArticleId IdType="pubmed">12631361</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr SH, Valeri AM, Cornell LD, et al. . Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775&#x2013;84. 10.2215/CJN.08300910</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.08300910</ArticleId><ArticleId IdType="pmc">PMC3069369</ArticleId><ArticleId IdType="pubmed">21441134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogo A, Qureshi N, Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993;22:367&#x2013;77. 10.1016/s0272-6386(12)70138-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0272-6386(12)70138-5</ArticleId><ArticleId IdType="pubmed">8372831</ArticleId></ArticleIdList></Reference><Reference><Citation>Payan Schober F, Jobson MA, Poulton CJ, et al. . Clinical features and outcomes of a racially diverse population with fibrillary glomerulonephritis. Am J Nephrol 2017;45:248&#x2013;56. 10.1159/000455390</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000455390</ArticleId><ArticleId IdType="pmc">PMC5482172</ArticleId><ArticleId IdType="pubmed">28161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat ZY, Zeng X, Hingorani J, et al. . Fibrillary glomerulonephritis in a patient with systemic lupus erythematosus: a rare association. Int Urol Nephrol 2013;45:281&#x2013;4. 10.1007/s11255-011-0073-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-011-0073-0</ArticleId><ArticleId IdType="pubmed">22102086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hvala A, Kobenter T, Ferluga D. Fingerprint and other organised deposits in lupus nephritis. Wien Klin Wochenschr 2000;112:15&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020962</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon S, Zeng X, Valentini R. Fibrillary glomerulonephritis and renal failure in a child with systemic lupus erythematosus. Pediatr Nephrol 2009;24:1577&#x2013;81. 10.1007/s00467-009-1168-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-009-1168-z</ArticleId><ArticleId IdType="pubmed">19308460</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeen NK, Troxell ML, Riazy M, et al. . Fibrillary glomerulonephritis: clinicopathologic features and atypical cases from a multi-institutional cohort. Clin J Am Soc Nephrol 2019;14:1741&#x2013;50. 10.2215/CJN.03870319</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03870319</ArticleId><ArticleId IdType="pmc">PMC6895488</ArticleId><ArticleId IdType="pubmed">31685544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan J, Restivo M, Canetta PA, et al. . Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant 2014;29:1925&#x2013;31. 10.1093/ndt/gfu189</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfu189</ArticleId><ArticleId IdType="pubmed">24867652</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>